Coronavirus (COVID-19) Collection
Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis
Coronavirus disease 2019 (COVID-19) is currently one of the most common diseases in the world, and has a considerable death toll (WHO, 2021). Although most patients have mild–moderate clinical manifestations, a significant proportion of patients develop life-threatening complications (Lim et al., 2020; Pranata et al., 2020a, 2021c). Complications caused by coagulopathy are among the most important. Activation of the coagulation pathway and endothelial cells (ECs) is a hallmark of severe COVID-19, which is consistent with high rates of venous thromboembolism (VTE), pulmonary embolism (PE) and disseminated intravascular coagulation (DIC) (Mancini et al., 2021a; Ward et al., 2021).Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates
Repurposing of available drugs for patients with coronavirus disease 2019 (COVID-19) has gained interest due to the scarcity of drugs proven to be useful in these patients. Dexamethasone, statins, metformin, dipeptidyl peptidase-4 inhibitors and renin–angiotensin system inhibitors have shown clinical benefits for severe and critically ill patients, especially those who are mechanically ventilated (Castiglione et al., 2020; Lim and Pranata, 2020a; Lukito et al., 2020; Pranata et al., 2020c; Rakhmat et al., 2021).
